PMCB — Pharmacyte Biotech Balance Sheet
0.000.00%
- $49.03m
- $34.77m
- 48
- 59
- 26
- 40
Annual balance sheet for Pharmacyte Biotech, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2.2 | 85.4 | 68 | 50.2 | 18.5 |
Net Total Receivables | — | — | — | — | 3.7 |
Prepaid Expenses | |||||
Total Current Assets | 2.28 | 85.5 | 68.1 | 50.4 | 22.4 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 7.4 | 90.6 | 73.3 | 59.9 | 55.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.725 | 0.704 | 0.587 | 7.42 | 2.91 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.725 | 0.704 | 0.587 | 20.4 | 3.28 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 6.68 | 89.9 | 72.7 | 39.5 | 51.9 |
Total Liabilities & Shareholders' Equity | 7.4 | 90.6 | 73.3 | 59.9 | 55.2 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |